Actelion Must Face Tracleer Antitrust Suit With Class Certified

By Bryan Koenig · September 6, 2024, 9:57 PM EDT

A Maryland federal judge refused Friday to toss an antitrust suit accusing Actelion Pharmaceuticals of illegally denying generics companies the samples they needed to produce generic versions of its hypertension drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Government Employees Health Association v. Actelion Pharmaceuticals Ltd. et al

Case Number

Court

Maryland

Nature of Suit

Anti-Trust

Date Filed

November 19, 2018

Recent Articles By Bryan

October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
August 28, 2024
Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit
August 14, 2024
Nursing Co. Exec Can't Split Up Fraud, Wage-Fixing Charges
August 12, 2024
9th Circ. Won't Rethink Upending Sutter Health Antitrust Win
July 31, 2024
Inhaler Patents 'Must Be' In Orange Book, Teva Tells Fed. Circ.
July 17, 2024
Heart Doctor's Sham Suit Claims Cut From Antitrust Row
July 11, 2024
Fed. Circ. Pauses Ouster Of Teva Patents From Orange Book